Genetics of HRT Response: Why Women React Differently

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on hormones and fertility. Browse all Hormones & Fertility education

The variability in how women respond to hormone support protocols is not random, not a prescribing error, and not a character of the specific compound being used. It is biological — and it is substantially genetic. Two women with the same symptoms, the same baseline hormone levels, and the same protocol can arrive at profoundly different clinical outcomes because the biological systems that govern estrogen production, metabolism, clearance, and cellular response are each individually variable at the genetic level. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including 6 Reproductive Health insights that map the complete genetic architecture of why estrogen-pathway protocols produce such different results in different women. This post synthesizes all six into a single framework for understanding the genetic basis of HRT response variability.

The Core Problem: Identical Input, Different Biology

Estrogen-pathway support delivers a defined input — a specific estrogen compound at a specific dose through a specific route. What that input encounters is not identical biology. Each woman's biological system processes the estrogen signal through a cascade of enzymatic and receptor steps that are each genetically individualized. The same dose of estradiol does not produce the same estradiol exposure, the same metabolite profile, the same clearance rate, or the same receptor-level signal in different women — because those outcomes are determined by genetic variables that operate independently of the dose itself.

Understanding which six variables matter, and why they compound rather than simply add, is the foundation for interpreting HRT response genetics. The satellite posts in this series cover each variable in depth individually; this post explains how they interact as a system.

Variable 1 — CYP1A1 / CYP1B1: How Estrogen Is Hydroxylated

Before estrogen can be cleared in Phase 2, it must be converted through Phase 1 hydroxylation by CYP1A1 and CYP1B1. These enzymes compete for the same estradiol substrate and route it toward two different catechol estrogen metabolites — 2-OHE2 (via CYP1A1, the lower-reactivity pathway) and 4-OHE2 (via CYP1B1, the higher-reactivity pathway). The ratio between these metabolites — shaped substantially by CYP1A1 and CYP1B1 genetic variants, particularly CYP1B1 Leu432Val — determines the downstream metabolic burden on every Phase 2 enzyme that follows.

In the context of hormone support, this matters immediately: any elevation in circulating estradiol provides more Phase 1 substrate. A woman with high-activity CYP1B1 generates proportionally more 4-OHE2 from that substrate than a woman with lower CYP1B1 activity at the same dose — loading more reactive metabolite into a Phase 2 system that must clear it. The Phase 1 genetic dimension is the entry point of the clearance cascade, and it sets the demand that all downstream Phase 2 enzymes must meet. Full detail in CYP1A1 and CYP1B1: Estrogen Metabolism Pathways.

Variable 2 — COMT Val158Met: The Primary Methylation Clearance Rate

COMT is the rate-limiting enzyme in Phase 2 methylation — the primary inactivation route for the catechol estrogens CYP1A1 and CYP1B1 produce. Val158Met (rs4680) determines whether COMT runs at high (Val/Val), intermediate (Val/Met), or slow (Met/Met) speed. Met/Met homozygosity reduces activity by approximately 60–75% relative to Val/Val across multiple tissue types.

For hormone support, COMT speed determines what happens to the 4-OHE2 that CYP1B1 produces. Fast COMT clears it rapidly, minimizing its dwell time, receptor activity, and quinone formation risk. Slow COMT allows it to accumulate — sustaining a stronger estrogenic signal at tissue receptors than the administered dose alone would suggest, and increasing the fraction that undergoes quinone-forming oxidation. This is why two women at the same estradiol level on the same protocol can have very different experiences of that estradiol's biological effect: their COMT genotype is shaping the catechol estrogen signal at tissue level in real time. Full detail in COMT Val158Met and Estrogen Clearance.

Variable 3 — MTHFR: The Upstream Methylation Supply Constraint

COMT's activity is genetically set by Val158Met — but its actual throughput depends on SAMe availability, and SAMe availability depends on MTHFR. MTHFR C677T and A1298C variants reduce the conversion of dietary folate to 5-MTHF, constraining the methyl group supply that the methylation cycle uses to regenerate methionine and synthesize SAMe. When MTHFR is impaired, COMT receives less methyl donor substrate and operates below even its Val158Met-determined capacity.

This creates a two-layer constraint: COMT genotype sets the ceiling for methylation speed; MTHFR-limited SAMe sets the actual operating level. A woman with Val/Val COMT (genetically fast) but T/T MTHFR (SAMe-constrained) may clear catechol estrogens more slowly than her COMT genotype alone would suggest — because her methyl donor supply is the limiting factor, not her enzyme structure. Understanding both variables together is essential for interpreting estrogen clearance capacity accurately. Full detail in MTHFR and Methylation: The Women's Hormone Connection.

Variable 4 — ESR1 / ESR2: Receptor Sensitivity — The Signal Reading Layer

All the upstream genetics — Phase 1 hydroxylation ratio, methylation clearance rate, sulfation clearance capacity — shape what estrogen signal arrives at receptors and how much remains after clearance. ESR1 and ESR2 genetics determine how sensitively the receptor system reads whatever signal does arrive. This is the terminal layer where HRT response differences become subjectively real for women.

ESR1 variants — particularly the PvuII-XbaI haplotype and poly-A repeat length in intron 6 — alter ERα expression efficiency in target tissues including bone, breast, cardiovascular endothelium, and hypothalamus. Higher-sensitivity ESR1 variants amplify the biological effect of a given estradiol concentration; lower-sensitivity variants attenuate it. ESR2 variants shape the ERα:ERβ balance — particularly in CNS tissues relevant to mood and vasomotor symptoms — determining whether the estrogenic signal generated by ERα is modulated or reinforced by ERβ activity.

A woman with low-sensitivity ESR1 variants may experience inadequate symptom relief at an estradiol level that produces strong effects in a woman with high-sensitivity ESR1 — not because the protocol is underdosed by population standards, but because her receptor system requires more signal to generate equivalent downstream activation. Conversely, high-sensitivity ESR1 may produce disproportionately strong estrogenic effects at conservative doses if clearance is also slow. Full detail in Estrogen Receptor Genetics: ESR1 and ESR2 Variants.

Variable 5 — SULT1A1: The Independent Sulfation Clearance Capacity

SULT1A1 sulfation runs parallel to COMT methylation — inactivating estradiol, estrone, and catechol estrogens through an entirely different enzymatic route that does not depend on SAMe or the methylation cycle. SULT1A1 Arg213His (rs9282861) determines whether this independent clearance route operates at full capacity (Arg/Arg), intermediate capacity (Arg/His), or near-absent capacity (His/His, approximately 85–90% activity reduction).

Two specific dimensions make SULT1A1 particularly relevant to HRT response:

Hepatic first-pass sulfation: Oral estrogen-pathway support routes estradiol through the liver before systemic circulation — subjecting it to first-pass SULT1A1 sulfation. High-activity Arg/Arg women sulfate a meaningful fraction of oral estradiol to inactive sulfate conjugates during first pass, affecting the proportion that reaches systemic receptors. Transdermal delivery bypasses hepatic first-pass entirely, making the pharmacokinetic difference between routes partly a function of SULT1A1 genotype. Providers who understand SULT1A1 can interpret route-of-delivery differences in blood estradiol levels more accurately.

Compensation when COMT is slow: When COMT methylation is constrained (by Met/Met genotype or MTHFR-limited SAMe), SULT1A1 carries a larger share of total Phase 2 clearance. His/His SULT1A1 eliminates that compensatory route — leaving slow COMT women without their most important backup. The COMT-SULT1A1 interaction is one of the most clinically significant genetic pairings in the Women's Hormone panel. Full detail in SULT1A1 Sulfation: Estrogen Detox Genetics.

Variable 6 — GSTM1 / GSTT1: The Tertiary Glutathione Backstop

GSTM1 and GSTT1 are not estrogen clearance enzymes in the primary sense — they are reactive metabolite detoxification enzymes that become most consequential when Phase 2 methylation and sulfation are insufficient. When 4-OHE2 is not rapidly cleared by COMT or SULT1A1, it oxidizes to reactive quinones — electrophilic species that can form depurinating DNA adducts. GSTM1 and GSTT1 conjugate these quinones with glutathione before they reach DNA.

Unlike the SNP-based variants of the other five dimensions, GSTM1 and GSTT1 null alleles are complete gene deletions — producing zero enzyme activity. Approximately 40–50% of women are GSTM1 null; 10–20% are GSTT1 null. Women who are null for either or both carry no enzymatic glutathione protection against reactive estrogen quinones — a silent predisposition that generates no symptoms and no blood marker until the rest of the clearance system is under sufficient pressure. In the context of HRT, elevated estradiol provides more Phase 1 substrate → more 4-OHE2 → higher quinone formation demand → more critical absence of the backstop. Full detail in GSTM1 and GSTT1: Glutathione and Hormone Detox.

Why These Six Variables Multiply — Not Just Add

Each of these six variables shapes a different step in the estrogen biology cascade. Each varies independently. The reason HRT response is so profoundly variable across women isn't that any single variable produces a wide range — it's that all six vary simultaneously, and their effects compound through the cascade rather than simply adding together.

Two illustrative profiles built from the full panel:

Profile A — High CYP1B1 · Met/Met COMT · T/T MTHFR · His/His SULT1A1 · GSTM1 null: Phase 1 generates elevated 4-OHE2 (CYP1B1). Primary methylation clearance is slow (COMT Met/Met). Methyl donor supply constrains COMT further below its genotypic capacity (MTHFR T/T). Independent sulfation backup is near-absent (SULT1A1 His/His). Glutathione backstop is gone (GSTM1 null). On any estrogen-pathway support approach that elevates circulating estradiol, this woman's Phase 2 system faces all clearance pathways simultaneously at their minimum. Reactive 4-OHE2 quinone burden accumulates — more receptor stimulation from catechol estrogen dwell time, more pressure on whatever non-enzymatic antioxidant defenses remain. A provider who sees only estradiol blood levels has no visibility into this architecture.

Profile B — Normal CYP1B1 · Val/Val COMT · C/C MTHFR · Arg/Arg SULT1A1 · GSTM1 present · Low ESR1 sensitivity: Phase 1 generates a favorable 2-OHE2:4-OHE2 ratio. Primary methylation clearance is fast. SAMe supply is unrestricted. Sulfation backup is at full capacity. Glutathione backstop is intact. But ERα receptor sensitivity is low — the estrogen signal that the efficient clearance system has shaped still generates a muted tissue-level response. This woman may experience inadequate symptom relief at doses that would produce strong effects in Profile A — not because her clearance is poor, but because her receptor isn't amplifying the signal. Her monitoring priority is receptor-level response, not clearance support.

Neither profile is better or worse. Both benefit from knowing their genetic architecture before protocols begin rather than discovering it through months of inadequate response, excessive effects, or unexplained side effects.

What Genetics Changes About HRT Planning — and What It Doesn't

Knowing these six variables doesn't determine what protocol a woman pursues, or whether to pursue one at all. Those are clinical decisions made in partnership with a qualified healthcare provider who weighs genetics alongside symptoms, bloodwork, health history, and individual goals. What genetics changes is the starting map — the terrain the provider and patient are navigating together.

A provider who knows a woman's CYP1B1 activity, COMT genotype, MTHFR status, SULT1A1 capacity, GSTM1/GSTT1 deletion status, and ESR1/ESR2 receptor sensitivity is working from a fundamentally more complete clinical picture than estradiol measurements alone can deliver. That picture changes:

Monitoring priorities. A woman with high CYP1B1 and slow COMT warrants closer attention to the downstream effects of elevated catechol estrogen burden. A woman with low ESR1 sensitivity warrants closer attention to whether symptomatic response reflects the actual circulating estradiol level. Different genetic profiles require different monitoring frameworks — not the same lab panel applied to everyone.

Methylation support decisions. MTHFR status informs whether methylated folate forms (5-MTHF rather than folic acid) and methylcobalamin should be established before or alongside any estrogen-pathway support approach — supporting COMT's SAMe supply proactively rather than reactively when clearance challenges emerge.

Response interpretation. When a woman reports inadequate symptom relief, unusual estrogenic effects, or unexpected side effects, her provider has a genetic framework for forming hypotheses about mechanism — rather than treating every response pattern as protocol-level guesswork. Genetics as a guide, not a guarantee — the genetic map doesn't predict outcomes, but it defines the biological terrain within which every outcome plays out.

The Complete Women's Hormone Panel: All Six Insights Together

The 6 Reproductive Health insights in the Precision Peptide Genetic Test are designed to be read as a system — not as six separate data points. Together they trace the complete estrogen biology cascade from Phase 1 hydroxylation (CYP1A1/CYP1B1) through Phase 2 methylation (COMT/MTHFR) and sulfation (SULT1A1) to glutathione backup (GSTM1/GSTT1) and receptor-level response (ESR1/ESR2). The full framework for why these six insights form a connected system — and what the panel reveals — is covered in the Complete Guide to Genetic Women's Hormone Testing.

Each satellite post in this series covers its gene in depth for women who want to understand a specific dimension before or after testing:

CYP1A1 and CYP1B1: Estrogen Metabolism Pathways — the Phase 1 hydroxylation dimension.

COMT Val158Met and Estrogen Clearance — the primary Phase 2 methylation dimension.

MTHFR and Methylation: The Women's Hormone Connection — the upstream methylation supply dimension.

Estrogen Receptor Genetics: ESR1 and ESR2 Variants — the receptor sensitivity dimension.

SULT1A1 Sulfation: Estrogen Detox Genetics — the independent sulfation clearance dimension.

GSTM1 and GSTT1: Glutathione and Hormone Detox — the tertiary glutathione backstop dimension.

The Precision Peptide Genetic Test analyzes how your genes influence hormone-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Ready to map all six dimensions of your estrogen genetics before your next hormone conversation? Take the Precision Peptide Genetic Test

Frequently Asked Questions About Genetics and HRT Response

Why do some women respond better to hormone support protocols than others?

At least six genetic variables shape individual response: CYP1A1/CYP1B1 (Phase 1 hydroxylation ratio), COMT Val158Met (methylation clearance speed), MTHFR (SAMe supply to COMT), ESR1/ESR2 (receptor sensitivity), SULT1A1 (sulfation capacity), and GSTM1/GSTT1 (glutathione backstop). The Precision Peptide Genetic Test analyzes all 6 Reproductive Health insights together — explaining variability that estradiol measurements alone cannot predict.

Can genetic testing tell me how I will respond to estrogen-pathway support?

Not in a predictive sense — but the Precision Peptide Genetic Test maps six variables that shape response: Phase 1 hydroxylation ratio, methylation clearance speed, SAMe supply, receptor sensitivity, sulfation capacity, and glutathione backstop. That genetic baseline gives providers meaningfully more clinical context than estradiol measurements alone can deliver.

What is the most important genetic variable for HRT response in women?

No single variable dominates — which is why single-gene analysis misses the full picture. CYP1B1 sets the reactive metabolite load; COMT sets primary clearance rate; MTHFR constrains SAMe; ESR1 determines receptor amplification; SULT1A1 provides sulfation backup; GSTM1/GSTT1 backstops quinones. The Precision Peptide Genetic Test analyzes all 6 Reproductive Health insights together.

This article is part of the PlexusDx Education Hub. Browse all Hormones & Fertility education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.